Schlaeppi B, Roncari G, Zahm P
F. Hoffmann-La Roche Ltd, Department of Toxicology, Basle, Switzerland.
Arch Toxicol. 1991;65(1):73-80. doi: 10.1007/BF01973506.
Necrotizing arteritis and periarteritis were found in Beagle and German Shepherd dogs treated for 13 or 52 weeks with the novel benzodiazepine receptor (BZR) partial agonist Ro 16-6028 (generic name bretazenil). Eight male and one female out of a total of 20 dogs treated with 40-60 mg/kg/day Ro 16-6028 developed the arteritis, predominantly in the heart or the epididymis. Two of these animals died prematurely following treatment at the initial dosing levels of 80 and 55 mg/kg/day; one of these two dogs was asymptomatic and in good general condition until death. Clinically, all but one of the dogs showed sedation, ataxia, stiff gait, body weight-loss and a deterioration of the general condition as well as changes of some laboratory parameters. No signs of arteritis and untoward clinical or laboratory findings were seen at lower doses. Possible aetiologies, as well as the mechanisms involved in arteritis in general and the genetic disposition of beagles in particular for this type of effect, are discussed. Reflections on the potential risk to man of this so far unknown finding after oral treatment with 1,4-benzodiazepines (BZs) are presented.
在用新型苯二氮䓬受体(BZR)部分激动剂Ro 16 - 6028(通用名布瑞氮䓬)治疗13周或52周的比格犬和德国牧羊犬中发现了坏死性动脉炎和动脉周围炎。在总共20只接受40 - 60mg/kg/天Ro 16 - 6028治疗的犬中,8只雄性和1只雌性出现了动脉炎,主要发生在心脏或附睾。其中两只动物在初始给药剂量为80mg/kg/天和55mg/kg/天时治疗后过早死亡;这两只狗中的一只在死亡前没有症状且总体状况良好。临床上,除一只狗外,所有狗都表现出镇静、共济失调、步态僵硬、体重减轻和总体状况恶化以及一些实验室参数的变化。在较低剂量下未观察到动脉炎迹象以及不良临床或实验室结果。讨论了可能的病因,以及一般动脉炎所涉及的机制,特别是比格犬对这种效应的遗传易感性。还介绍了对口服1,4 - 苯二氮䓬(BZs)后这一迄今未知发现对人类潜在风险的思考。